FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2949837617> ?p ?o ?g. }

• W2949837617 abstract "Background: Psoriatic arthritis (PsA) is a chronic inflammatory disease resulting in significant symptom burden.1 Over time and without adequate treatment, PsA can lead to disability and reduced patient quality of life.2 Fatigue is among the most common symptoms,1 but is complex and difficult to measure. The most burdensome symptoms that impact PsA patients need to be better understood in order to select patient reported outcomes (PRO) tools that adequately capture these concepts. Objectives: 1.) Identify the signs and symptoms of PsA experienced by patients, with a focus on fatigue, and how the disease and its treatment(s) impact patients’ lives. 2.) assess the content validity of select PRO instruments and items to measure fatigue. Methods: Qualitative interviews were conducted among patients with PsA recruited through the forWARD databank. The most frequently experienced symptoms and impacts of PsA and the degree to which they disturbed patients’ lives, were tabulated. Disturbance was evaluated on a scale from 0 (not at all) to 10 (greatly disturbs). Patients reporting fatigue were probed to describe the experience in their own words, and descriptors were recorded. Interviews were conducted and assessed on a rolling basis and recruitment continued until concept saturation was achieved. Results: Nineteen PsA patients were interviewed for this study. A core set of PsA symptoms were identified by nearly all patients and with moderate to high average disturbance ratings (Figure 1): joint pain, skin symptoms, stiffness, swollen/inflamed joints, and fatigue. The most salient impacts (Figure 2) were sleep disturbance, physical disability, effects on daily activities, and feelings of frustration. Most common descriptors of fatigue included “fatigue,” “tiredness,” “lack of energy,” “mental fatigue,” and “exhaustion.” Conclusion: Salient symptoms were consistent with those previously reported, along with a broader range of symptoms and impacts, which included fatigue. In addition to physical disability, others such as sleep disturbance, frustration, and effect of daily activities were common high impact themes that emerged. References [1] Dures, E., et al. (August2017). Important treatment outcomes for patients with psoriatic arthritis: a multisite qualitative study. Patient (10). Retrieved fromhttps://www.ncbi.nlm.nih.gov/pubmed/28229377 [2] Orbai, a., et al. (April2017). International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. Annals of Rheumatic Disorders, 76(4). Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/27613807 Disclosure of interests: Alexis Ogdie Grant/research support from: (To my university) Novartis, Pfizer, Grant/research support from: Novartis, Pfizer, Grant/research support from: Novartis, Pfizer, Grant/research support from: Novartis, Pfizer, Consultant for: abbVie, Bristol-Myers Squibb, Celgene, Corrona, Eli Lilly and Company, Novartis, Pfizer, and Takeda, Consultant for: abbVie, amgen, Bristol-Myers Squibb, Celgene, Corrona, Eli Lilly, Novartis, Pfizer inc, Takeda, Consultant for: abbvie, amgen, BMS, Celgene, Corrona, Lilly, Novartis, Pfizer, Takeda, Consultant for: abbvie, amgen, BMS, Celgene, Corrona, Lilly, Novartis, Pfizer, Takeda, Kaleb Michaud Grant/research support from: Pfizer (within past 2 years), Evo alemao Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, Miroslawa Nowak Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, Rachel Bruce Consultant for: Bristol-Myers Squibb, Kendra DeBusk Shareholder of: Bristol-Myers Squibb, Roche, Employee of: Bristol-Myers Squibb (current), Roche (former), Sarah Cantor Consultant for: Bristol-Myers Squibb, Carlijn Hintzen Consultant for: Bristol-Myers Squibb, Philip J Mease Grant/research support from: abbVie, amgen, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer, SUN and UCB, Consultant for: abbVie, amgen, BMS, Galapagos, Gilead Sciences, inc., Janssen, Lilly, Novartis, Pfizer, SUN and UCB, Speakers bureau: abbVie, amgen, BMS, Celgene, Genentech, Janssen, Lilly, Novartis, Pfizer and UCB" @default.
• W2949837617 created "2019-06-27" @default.
• W2949837617 creator A5008426193 @default.
• W2949837617 creator A5014427334 @default.
• W2949837617 creator A5020888980 @default.
• W2949837617 creator A5044067217 @default.
• W2949837617 creator A5048003509 @default.
• W2949837617 creator A5048628555 @default.
• W2949837617 creator A5056305723 @default.
• W2949837617 creator A5081778211 @default.
• W2949837617 creator A5087320027 @default.
• W2949837617 date "2019-06-01" @default.
• W2949837617 modified "2023-09-28" @default.
• W2949837617 title "AB0770 SYMPTOMS AND IMPACTS IN PSORIATIC ARTHRITIS: FINDINGS FROM QUALITATIVE PATIENT INTERVIEWS" @default.
• W2949837617 doi "https://doi.org/10.1136/annrheumdis-2019-eular.4349" @default.
• W2949837617 hasPublicationYear "2019" @default.
• W2949837617 type Work @default.
• W2949837617 sameAs 2949837617 @default.
• W2949837617 citedByCount "0" @default.
• W2949837617 crossrefType "proceedings-article" @default.
• W2949837617 hasAuthorship W2949837617A5008426193 @default.
• W2949837617 hasAuthorship W2949837617A5014427334 @default.
• W2949837617 hasAuthorship W2949837617A5020888980 @default.
• W2949837617 hasAuthorship W2949837617A5044067217 @default.
• W2949837617 hasAuthorship W2949837617A5048003509 @default.
• W2949837617 hasAuthorship W2949837617A5048628555 @default.
• W2949837617 hasAuthorship W2949837617A5056305723 @default.
• W2949837617 hasAuthorship W2949837617A5081778211 @default.
• W2949837617 hasAuthorship W2949837617A5087320027 @default.
• W2949837617 hasBestOaLocation W29498376171 @default.
• W2949837617 hasConcept C118552586 @default.
• W2949837617 hasConcept C126322002 @default.
• W2949837617 hasConcept C144024400 @default.
• W2949837617 hasConcept C144133560 @default.
• W2949837617 hasConcept C1513209611 @default.
• W2949837617 hasConcept C159110408 @default.
• W2949837617 hasConcept C162853370 @default.
• W2949837617 hasConcept C1862650 @default.
• W2949837617 hasConcept C190248442 @default.
• W2949837617 hasConcept C2776260265 @default.
• W2949837617 hasConcept C2777077863 @default.
• W2949837617 hasConcept C2779951463 @default.
• W2949837617 hasConcept C2781210498 @default.
• W2949837617 hasConcept C36289849 @default.
• W2949837617 hasConcept C56995899 @default.
• W2949837617 hasConcept C71924100 @default.
• W2949837617 hasConcept C79544238 @default.
• W2949837617 hasConceptScore W2949837617C118552586 @default.
• W2949837617 hasConceptScore W2949837617C126322002 @default.
• W2949837617 hasConceptScore W2949837617C144024400 @default.
• W2949837617 hasConceptScore W2949837617C144133560 @default.
• W2949837617 hasConceptScore W2949837617C1513209611 @default.
• W2949837617 hasConceptScore W2949837617C159110408 @default.
• W2949837617 hasConceptScore W2949837617C162853370 @default.
• W2949837617 hasConceptScore W2949837617C1862650 @default.
• W2949837617 hasConceptScore W2949837617C190248442 @default.
• W2949837617 hasConceptScore W2949837617C2776260265 @default.
• W2949837617 hasConceptScore W2949837617C2777077863 @default.
• W2949837617 hasConceptScore W2949837617C2779951463 @default.
• W2949837617 hasConceptScore W2949837617C2781210498 @default.
• W2949837617 hasConceptScore W2949837617C36289849 @default.
• W2949837617 hasConceptScore W2949837617C56995899 @default.
• W2949837617 hasConceptScore W2949837617C71924100 @default.
• W2949837617 hasConceptScore W2949837617C79544238 @default.
• W2949837617 hasLocation W29498376171 @default.
• W2949837617 hasOpenAccess W2949837617 @default.
• W2949837617 hasPrimaryLocation W29498376171 @default.
• W2949837617 hasRelatedWork W2949792734 @default.
• W2949837617 hasRelatedWork W2950668732 @default.
• W2949837617 hasRelatedWork W2950975041 @default.
• W2949837617 hasRelatedWork W2951065114 @default.
• W2949837617 hasRelatedWork W2951114933 @default.
• W2949837617 hasRelatedWork W2951409490 @default.
• W2949837617 hasRelatedWork W2951880153 @default.
• W2949837617 hasRelatedWork W2952209514 @default.
• W2949837617 hasRelatedWork W2952388326 @default.
• W2949837617 hasRelatedWork W2952544913 @default.
• W2949837617 hasRelatedWork W2952566230 @default.
• W2949837617 hasRelatedWork W2953165292 @default.
• W2949837617 hasRelatedWork W3033058239 @default.
• W2949837617 hasRelatedWork W3033809365 @default.
• W2949837617 hasRelatedWork W3049488785 @default.
• W2949837617 hasRelatedWork W3123163825 @default.
• W2949837617 hasRelatedWork W3124449102 @default.
• W2949837617 hasRelatedWork W3164450791 @default.
• W2949837617 hasRelatedWork W3164503965 @default.
• W2949837617 hasRelatedWork W3164879169 @default.
• W2949837617 isParatext "false" @default.
• W2949837617 isRetracted "false" @default.
• W2949837617 magId "2949837617" @default.
• W2949837617 workType "article" @default.